1. Introduction {#sec1-diseases-06-00043}
===============

Rare diseases, namely conditions with incidence rates lower than 1:2000 affect an estimated 350 million people worldwide. More than 7000 such diseases have already been described, and 80% of these are thought to have genetic origins \[[@B1-diseases-06-00043],[@B2-diseases-06-00043],[@B3-diseases-06-00043],[@B4-diseases-06-00043]\]. Approximately one out of 15 infants born worldwide will be affected by a rare hereditary disease during their lifetime \[[@B5-diseases-06-00043]\]. 50--75% of these diseases affect children, and one third of children born with such a condition die before their fifth birthday \[[@B1-diseases-06-00043]\].

The advent of novel methodologies (e.g., next-generation sequencing (NGS)) has made efforts to identify the genetic causes of rare diseases easier, faster and cheaper, yet an accurate molecular diagnosis is still far from trivial with our current knowledge \[[@B4-diseases-06-00043]\]. Disease mapping with current technologies will often yield multiple hits. Many of the flagged alleles are rare variants with unknown effects of genes with known function, or deleterious-looking variants of unknown genes. Deciding which one of these hits is the causative mutation behind the observed phenotype can be a formidable challenge, but often these hard questions can be successfully tackled with the help of model organism genetics \[[@B6-diseases-06-00043]\].

Over the past four decades zebrafish has become one of the most in-demand genetic organisms \[[@B7-diseases-06-00043],[@B8-diseases-06-00043],[@B9-diseases-06-00043],[@B10-diseases-06-00043]\]. Researchers have realized early on that this small freshwater fish species bears several characteristics of an ideal vertebrate genetic model organism (it is cheap to maintain, has a small size, is transparent in the embryonic stage, has an external fertilization and a relatively short generation time). But it was the advent of an easy-to-use and ever expanding genetic toolkit that made the zebrafish hugely popular.

The first successful large-scale forward genetic screens \[[@B11-diseases-06-00043],[@B12-diseases-06-00043]\] resulted in a treasure trove of important mutants and demonstrated that this approach can be applied to find mutations with biomedical relevance \[[@B13-diseases-06-00043]\]. Publication of the first detailed genetic maps \[[@B14-diseases-06-00043],[@B15-diseases-06-00043],[@B16-diseases-06-00043],[@B17-diseases-06-00043]\] and sequencing the full diploid zebrafish genome \[[@B18-diseases-06-00043]\] has made the previously challenging and tedious positional mapping of the mutations much more straightforward \[[@B19-diseases-06-00043]\]. Recent systematic efforts, such as the Zebrafish Mutation Project (ZMP) coordinated by the Sanger Institute (UK), aim to mutate every gene in the zebrafish genome (up to date 37,624 alleles of 14,934 genes have been created) \[[@B20-diseases-06-00043]\] and advances in NGS technology offer a far more rapid and straightforward solution for the mapping of novel mutations \[[@B21-diseases-06-00043],[@B22-diseases-06-00043]\].

While zebrafish has been used primarily in developmental studies, over the past two decades it has also become one of the most relevant model organisms used in human pathogenetic studies \[[@B5-diseases-06-00043],[@B6-diseases-06-00043],[@B23-diseases-06-00043],[@B24-diseases-06-00043],[@B25-diseases-06-00043]\].

As a vertebrate organism, zebrafish shares many anatomical features with humans. Furthermore, a high level of genetic conservation can be observed between the two species. Sequencing of the zebrafish genome revealed that 71% of all human proteins and 82% of disease causing ones have a zebrafish ortholog \[[@B5-diseases-06-00043],[@B18-diseases-06-00043]\]. Compared with the genes included in the recently published PedAM database of pediatric disease annotation \[[@B26-diseases-06-00043]\] we found that \~75% (13,217/17,727) of PedAM genes have a clear zebrafish ortholog ([Figure 1](#diseases-06-00043-f001){ref-type="fig"}).

All these advantages, supplemented with an advanced genetic toolkit (see below) make zebrafish uniquely suited for studying human diseases, and for the screening of potential drugs \[[@B5-diseases-06-00043],[@B6-diseases-06-00043]\]. Accordingly, the use of zebrafish features prominently in several large international collaborations (e.g., Undiagnosed Diseases Network (UDN) and Rare Diseases Models and Mechanisms (RDMM)) that aim to study potential disease causing genes with the help of model organisms \[[@B6-diseases-06-00043]\].

2. The Zebrafish Genetic Toolkit {#sec2-diseases-06-00043}
================================

Forward genetic approaches, which are used for the identification of mutated genes underpinning specific phenotypes of interest are complemented by reverse genetic approaches, of which antisense morpholino oligonucleotides, morpholinos (MOs) have been the most popular \[[@B27-diseases-06-00043]\]. While the expansion of the zebrafish genetic toolbox has increased the model's appeal, it is important to keep in mind the limits of the model and some experimental approaches.

For example, when designing experiments with zebrafish orthologs of particular human disease genes it is worth remembering that due to a whole genome duplication in the Teleost lineage, some human genes have two zebrafish paralogs (\[[@B18-diseases-06-00043]\]). Often, but not always, these paralogs show signs of subfunctionalization (\[[@B28-diseases-06-00043],[@B29-diseases-06-00043],[@B30-diseases-06-00043]\]). Therefore, while for some disease models the knock-down of both paralogs will be necessary, in other cases knocking down a single paralog could give a phenotype that is equivalent to the one observed in human patients.

2.1. Transient Genetic Approaches {#sec2dot1-diseases-06-00043}
---------------------------------

Synthetic MO oligos are very stable and can be easily injected into embryos at 1--2 cell stage, where they interfere with gene expression. MOs can bind and mask the translational start site of mRNAs, or can interfere with splicing, in effect creating loss-of-function phenotypes. This straightforward and simple approach became extremely popular among researchers looking for quick assays to test candidate genes from NGS/Genome Wide Association Studies (GWAS), and in numerous studies MO-based experiments and the resulting morphant phenotypes provided the necessary proof to validate the identification of disease genes ([Table 1](#diseases-06-00043-t001){ref-type="table"}). They can be also used as genetic proof by phenocopy when mapping mutants from forward genetic screens.

Although MO technology was enthusiastically adopted by the zebrafish field and morphant phenotypes were often used in human genetic studies to provide independent proof for the involvement of particular genes in the observed pathologies, the approach has important limitations. For example, MO injections (just like mRNA injections) will have transient effects (see later). But just as important is the fact that MOs can elicit strong, specific p53-dependent effects \[[@B31-diseases-06-00043]\] and recent analysis has also shown that the activation of an innate immune response and off-target miss-splicing are common side effects of MO usage \[[@B32-diseases-06-00043]\]. Furthermore, some early studies of genome-edited lines have raised serious questions about the veracity of many results that were based on MO-effects only (\[[@B33-diseases-06-00043]\]). All these findings resulted in a reconsideration of the use of MOs in the zebrafish field and paved the way to stringent new guidelines \[[@B34-diseases-06-00043],[@B35-diseases-06-00043]\].

It would be easy to conclude that a morphant phenotype should be considered specific only if it is able to phenocopy a mutation. However, recent research suggests that the unaltered phenotype in many zebrafish mutants could be the result of either genomic compensation triggered by non-sense mediated decay \[[@B36-diseases-06-00043],[@B37-diseases-06-00043]\] or altered mRNA processing \[[@B38-diseases-06-00043],[@B39-diseases-06-00043]\]. These compensatory effects are not apparent in transcriptional knock-downs, such as MOs and CRISPR-interference (CRISPRi). Overall, the current consensus in the field is to consider MO results specific not only when there is a mutant allele with an identical phenotype, but also if the injection of the MO into the mutant background has no visible phenotypic effects, even though there are differences between the phenotypes of the morphants and mutants of a particular gene.

If a *bona fide* mutant for the gene of interest is not available, it is of utmost importance to use proper controls when working with MOs. These include the use of multiple MOs, their careful titration and the demonstration that the gene of interest is successfully targeted (either by Western blot if antibodies are available, or at least by RT-PCR to monitor altered splicing in the case of a splice blocking MO).

Similarly to MOs, in vitro synthesized mRNAs can be introduced easily into early stage embryos. These methodologically easy and quick gain-of-function experiments have been widely used to decipher the role of genes during early development. As mRNA injection can be used to express dominant-negative or constitutively active constructs, too, in combination with MOs, it has been successfully applied for epistasis analysis experiments \[[@B40-diseases-06-00043]\]. (Co)injection of mRNAs has been also widely used as genetic proof to validate the specificity of morphant and mutant phenotypes.

2.2. Stable Genetic Approaches {#sec2dot2-diseases-06-00043}
------------------------------

Only with the application of TALEN-based \[[@B114-diseases-06-00043],[@B115-diseases-06-00043],[@B116-diseases-06-00043]\] and, more recently, CRISPR/Cas9-based genome editing technologies in zebrafish \[[@B117-diseases-06-00043],[@B118-diseases-06-00043],[@B119-diseases-06-00043],[@B120-diseases-06-00043],[@B121-diseases-06-00043],[@B122-diseases-06-00043]\] has the use of MOs seen a decline. These new methodological approaches have already revolutionized zebrafish genetics \[[@B123-diseases-06-00043]\] and provided independent means to test the veracity of the morphant phenotypes (see above). While most of the novel genome edited lines are loss-of-function alleles that arise due to the indel mutations resulting from erroneous non-homologous end joining (NHEJ) DNA repair mechanisms, efforts have been made to create precise knock-in alleles exploiting the alternative, homologous recombination (HR) repair pathway \[[@B124-diseases-06-00043],[@B125-diseases-06-00043],[@B126-diseases-06-00043]\]. While the excitement caused by these early results seemed justified, later results suggested that the knock-in efficiency is highly locus- (and template-) dependent.

Of the existing programmable nuclease techniques TALENs, albeit slower and more expensive to assembly, are usually considered superior, due to their higher specificity. The off-target effects of CRISPR can be, however, considerably reduced with the right choice of sgRNAs and with the use of rationally engineered Cas-variants \[[@B127-diseases-06-00043],[@B128-diseases-06-00043]\].

As the problems with MOs became apparent, many people opted to complement or supplement MO studies with the description of "crispant" phenotypes (see [Table 1](#diseases-06-00043-t001){ref-type="table"}). In crispants CRISPR/Cas9 technology was used to introduce mutation(s) with gene-specific sgRNA. In case of embryonic- or larval-lethal mutations, this approach could provide a quick and cost-effective way to test the function of the genes of interest. Due to the very nature of this method, however, most embryos will be highly mosaic for the mutations they carry, and only careful analysis can reveal if they indeed have biallelic mutations in most of their cells. Therefore, we should tread carefully and only accept crispant phenotypes as specific if constitutive mutants show the same phenotype. (Ideally, one should aim to conduct studies in F2 or F3 generations, where the possible confounding effects of off-target mutations can be minimized). It will be also important to compile databases of proven and effective sgRNA target sequences with low off-target effects, so that targeting of particular genes with CRISPR-based methods can become more standardized \[[@B129-diseases-06-00043]\].

The advantages of *bona fide* mutants over morphants and crispants are numerous, however, as mentioned above, the phenomenon of genetic compensation can hinder the characterization of mutant phenotypes \[[@B36-diseases-06-00043],[@B37-diseases-06-00043],[@B38-diseases-06-00043],[@B39-diseases-06-00043]\].

The transparency of zebrafish embryos and larvae has been long considered one of the most advantageous attributes of the model. Organs, tissues or specific cells can be labeled with fluorescent dyes and markers and followed in vivo under a microscope. Transgenic lines have been instrumental in characterizing the effects of specific mutations (e.g., \[[@B44-diseases-06-00043],[@B52-diseases-06-00043],[@B58-diseases-06-00043],[@B130-diseases-06-00043]\]), highlighting the power of this approach. The modular, easy-to-use "Tol2-kit", based on the Gateway technology has made the creation of transgenic lines a mundane task \[[@B131-diseases-06-00043]\]. Efficient transgenesis techniques have been also used for enhancer-trap and gene-trap screens \[[@B132-diseases-06-00043],[@B133-diseases-06-00043]\], and a wide array of tissue-specific Gal4 and CreERT2 lines have been established, paving the way for intricate genetic manipulations \[[@B134-diseases-06-00043],[@B135-diseases-06-00043],[@B136-diseases-06-00043]\].

Finally, the combination of transgenesis and genome editing techniques enabled researchers to create the conditional knock-out methodology that previously eluded the zebrafish field \[[@B137-diseases-06-00043],[@B138-diseases-06-00043]\].

3. Modeling Disease with Homologs and Phenologs {#sec3-diseases-06-00043}
===============================================

In the past few decades zebrafish has emerged as a powerful model of congenital disorders ([Table 1](#diseases-06-00043-t001){ref-type="table"}). This development is partly due to the advantages of the model (embryonic development is fast and external, therefore, the emergence of particular impairments can be followed effectively in real time and phenotypes can be identified early), but also to the limitation of the tools used. For example, although MOs can bring almost complete knock-down, their effect is temporary, and after 3--5 days it diminishes sharply \[[@B139-diseases-06-00043]\]. mRNAs are equally unstable (or even more so), thus their effect is limited to the first 2--3 days of development. Importantly, unlike many disease alleles in humans, the majority of zebrafish alleles for the respective genes isolated in previous screens or created recently with novel editing methods are embryonic-lethal null-alleles.

Despite these limitations MO-based knockdowns (lately backed up by crispant phenotypes, resulting from the injection of CRISPR/Cas9 RNPs into embryos) have been very successfully used in identifying driver genes for particular diseases. In a recent study of DiGeorge syndrome fish models have been essential to demonstrate that haplo-insufficiency of *CRKL* is the main cause of the kidney pathologies observed in patients with this syndrome \[[@B44-diseases-06-00043]\].

Due to the high levels of genetic and anatomical conservation between the two species, zebrafish models often display highly similar phenotypes to the human condition. For example, models of coloboma, generalized arterial calcification of infancy (GACI), X-linked adrenoleukodystrophy (ALD), Duchenne's muscular dystrophy or Dravet syndrome all display features that are highly similar to the characteristics of the human pathologies (see [Table 1](#diseases-06-00043-t001){ref-type="table"} for references).

In certain cases prior in-depth knowledge about zebrafish development helps to create highly informative disease models through orthologous phenotypes, or phenologs \[[@B140-diseases-06-00043]\]. For example, zebrafish models have been instrumental in deciphering the role of several genes in ciliopathies, such as Bardet-Biedl Syndrome (BBS) or Joubert syndrome ([Table 1](#diseases-06-00043-t001){ref-type="table"}). The popularity of zebrafish in ciliopathy research can be at least partly explained by the fact that dysfunction of the cilia results in easily recognizable developmental phenotypes, including curved body axis, hydrocephalus and laterality defects \[[@B141-diseases-06-00043]\].

Another excellent example for the use of phenologs in modeling pediatric disorders is fibrodysplasia ossificans progressiva (FOP). In-depth knowledge about the molecular mechanism of early dorso-ventral (DV) patterning in zebrafish development, including the phenotype of ventralized embryos, has been helpful both in the identification of the causative mutations of FOP \[[@B63-diseases-06-00043],[@B64-diseases-06-00043]\] and that of putative drugs \[[@B142-diseases-06-00043]\].

Constitutively active mutations, such as the ones observed in *ACVR1* in patients with FOP, can be modeled using mRNA injections and transgenic approaches. This approach can substitute or complement transient expression studies when necessary \[[@B65-diseases-06-00043]\]. Overexpression experiments can be also informative in modeling microduplications or trisomies \[[@B70-diseases-06-00043],[@B90-diseases-06-00043]\].

Finally, although MOs are usually injected in significant excess to obtain functional knock-downs, they can be also titrated to suboptimal concentrations to mimic the additive effects of hypomorphic mutations. A nice example for this approach is provided by the modeling of the Charcot-Marie-Tooth syndrome, where the "mutational burden" hypothesis of neuropathy genes was tested \[[@B53-diseases-06-00043]\].

4. Drug Discovery Using Zebrafish {#sec4-diseases-06-00043}
=================================

Its small size, allowing for semi-high-throughput screening, has made zebrafish a prominent model in drug screens over the past decade. In addition, due to the aforementioned high level of genetic conservation between zebrafish and humans, several drugs have similar targets (and thus similar effects) in both species. It is, therefore, no wonder that over the past decade zebrafish has emerged as the model organism of choice for high-throughput screening of chemical libraries for potential drugs \[[@B5-diseases-06-00043]\] and several compounds picked up in these screens have made their ways into clinical trials \[[@B143-diseases-06-00043]\].

Several models of pediatric disorders have been used in such screens, and these experiments confirm that both homologous and orthologous phenotypes can be successfully used in drug discovery/testing experiments ([Table 2](#diseases-06-00043-t002){ref-type="table"}). For example, a recent model of childhood-onset parkinsonism-dystonia, characterized by mutations in a Mn-transporter, was successfully used to show that the symptoms of the disease can be ameliorated using Na~2~CaEDTA as a chelator--and this treatment also alleviates the patients' symptoms \[[@B54-diseases-06-00043]\].

Identification of the causative FOP mutations in the *ACVR1* gene and the validation of the orthologous ventralized phenotypes in zebrafish led to the later discovery of dorsomorphin and its derivatives \[[@B142-diseases-06-00043]\]. These molecules with dorsalizing effects are currently being tested in clinical trials for FOP treatment. An even more impressive recent "aquarium to bedside" story involves a zebrafish model of Dravet syndrome: a high-throughput drug screen identified clemizole and lorcaserine as potential drugs with anti-serotonin effects. These drugs have been approved by the FDA earlier as an antihistamine and a weight-loss aid, respectively. It was, therefore, possible to register them as potential treatment without having to repeat the expensive, time-consuming clinical trials that enabled them to be approved. When applied directly to patients with Dravet syndrome, these repurposed drugs outperformed conventional anticonvulsants \[[@B144-diseases-06-00043]\].

While zebrafish studies will not always substitute pre-clinical tests in mammalian models, they can save time and money by pre-filtering the compounds that enter the more advanced phases of drug development (\[[@B5-diseases-06-00043],[@B145-diseases-06-00043]\]).

5. Outlook {#sec5-diseases-06-00043}
==========

Overall, despite the aforementioned limitations that can be overcome with proper controls or novel technologies, zebrafish models of rare pediatric diseases (and diseases in general) are set to probably become even more important assets of preclinical research and drug discovery in the coming years. We can almost certainly expect a proliferation of the repurposing studies of FDA-approved drugs, as zebrafish is the ideal model to conduct such studies. The increasing relevance of fish models will be also apparent in the study of childhood leukemias and other forms of cancer (for comprehensive reviews on this subject see \[[@B148-diseases-06-00043],[@B149-diseases-06-00043],[@B150-diseases-06-00043]\]) and zebrafish "avatars" for the development of personalized chemotherapies could also become prominent in the near future (\[[@B151-diseases-06-00043],[@B152-diseases-06-00043],[@B153-diseases-06-00043]\]).

With the proliferation of base-editor tools that are often based on synthetic versions of Cas-nucleases with altered PAM recognition sites, genome editing has entered a new phase, often referred as "CRISPR 2.0" (\[[@B154-diseases-06-00043],[@B155-diseases-06-00043],[@B156-diseases-06-00043],[@B157-diseases-06-00043]\]). We can routinely engineer A to G and C to T transitions with high precision in the genome, and as zebrafish has been at the forefront of the CRISPR-revolution, it is almost certain that the coming years will see a proliferation in the use of these base editors. This technological breakthrough will help us create exact or almost exact mimics of hypomorphic human disease alleles (instead of nulls), making the new disease model strains even more relevant in examining particular aspects of human pathologies. We can also expect the proliferation of "humanized" zebrafish lines as well, where zebrafish carrying mutations in particular genes are supplemented with a transgenic cassette expressing the human ortholog of the gene (\[[@B158-diseases-06-00043]\]). Zebrafish models created with precision base-editing methods could also help understanding how rare variants of Mendelian genes contribute significantly to complex disease phenotypes, as suggested by recent research \[[@B159-diseases-06-00043]\].

Finally---and somewhat counterintuitively---even the fact that zebrafish mutants often lack an overt phenotype could be exploited to better understand human diseases \[[@B39-diseases-06-00043]\]. Recent studies suggest that in certain unaffected individuals who are homozygotes or compound heterozygotes for null alleles, the effect of these loss-of-function alleles can be negligible \[[@B160-diseases-06-00043]\]. The study of mutant zebrafish strains that are phenotypically normal could reveal how their robustness is achieved by translational plasticity \[[@B161-diseases-06-00043]\], providing important insights into the context dependency of genetic risk factors.

The authors would like to thank Gaia Gestri, Julianna Víg and one anonymous reviewer for useful comments on the manuscript.

All authors contributed to the drafting of the paper and approved of the final manuscript.

This study was supported by grants MTA-SE Lendület Research Grant (LP2015-11/2015) of the Hungarian Academy of Sciences to K.T. and NRDI-FK124230 financed by the Hungarian National Research, Development and Innovation Office to M.V., M.V. is supported by the ÚNKP-17-4 New National Excellence Program of the Ministry of Human Capacities.

The authors declare no conflict of interest.
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A representative list of existing zebrafish pediatric disease models.

  Disease Name                                               ICD-10   Genes Targeted in Models                                                                                                                                  OMIM IDs                                                                                Model Type         References
  ---------------------------------------------------------- -------- --------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Diseases of the blood and blood forming organs                                                                                                                                                                                                                                                                                           
  Blackfan-Diamond anemia                                    D61.0    *RPS19*, *RPL11*, *RPS7*                                                                                                                                  105650, 612562, 603658                                                                  MO, mutant         \[[@B41-diseases-06-00043],[@B42-diseases-06-00043],[@B43-diseases-06-00043]\]
  DiGeorge syndrome                                          D82.1    *SNAP29*, *AIFM3*, *CRKL*                                                                                                                                 604202, 617298, 602007                                                                  MO, crispant       \[[@B44-diseases-06-00043]\]
  Reticular dysgenesis                                       D81.0    *AK2*                                                                                                                                                     267500                                                                                  MO                 \[[@B45-diseases-06-00043]\]
  Sideroblastic anemia (AR)                                  D64.0    *SLC25A38*                                                                                                                                                205950                                                                                  MO                 \[[@B46-diseases-06-00043]\]
  X-linked sideroblastic anemia                              D64.0    *ALAS2*                                                                                                                                                   300751                                                                                  mutant             \[[@B47-diseases-06-00043]\]
  Endocrine and metabolic diseases                                                                                                                                                                                                                                                                                                         
  Batten disease (Juvenile neuronal ceroid lipofuscinosis)   E75.4    *CLN3*, *TPP1*                                                                                                                                            204200, 204500                                                                          mutant, MO         \[[@B48-diseases-06-00043],[@B49-diseases-06-00043]\]
  Menkes disease                                             E83.0    *ATP7A*                                                                                                                                                   309400                                                                                  mutant             \[[@B50-diseases-06-00043]\]
  Nephropatic infantile cystinosis                           E72.0    *CTNS*                                                                                                                                                    219800                                                                                  mutant             \[[@B51-diseases-06-00043]\]
  X-linked adrenoleukodystrophy (ALD)                        E71.3    *ABCD1*                                                                                                                                                   300100                                                                                  mutant             \[[@B52-diseases-06-00043]\]
  Diseases of the nervous system                                                                                                                                                                                                                                                                                                           
  Charcot-Marie-Tooth syndrome                               G60.0    *MFN2*, *GDAP1*, *ABHD12*, *MED25*, *HSPB1*, *WNK1*                                                                                                       608507, 606598, 613599, 610197, 602195, 605232                                          MO                 \[[@B53-diseases-06-00043]\]
  Childhood-onset parkinsonism-dystonia                               *SLC39A14*                                                                                                                                                617013                                                                                  mutant             \[[@B54-diseases-06-00043]\]
  Dravet syndrome                                            G40.4    *SCN1A*                                                                                                                                                   182389                                                                                  mutant             \[[@B55-diseases-06-00043]\]
  Duchenne muscular dystrophy                                G71.0    *DMD*                                                                                                                                                     310200                                                                                  mutant             \[[@B56-diseases-06-00043]\]
  Generalized epilepsy with febrile seizures-plus            G40.3    *STX1B*                                                                                                                                                   616172                                                                                  MO                 \[[@B57-diseases-06-00043]\]
  Spinal muscular atrophy                                    G12      *SMN1*                                                                                                                                                    600354                                                                                  MO, mutant         \[[@B58-diseases-06-00043],[@B59-diseases-06-00043]\]
  Diseases of the circulatory system                                                                                                                                                                                                                                                                                                       
  Dilated cardiomyopathy                                     I42.0    *BAG3*                                                                                                                                                    603883                                                                                  MO, transgenic     \[[@B60-diseases-06-00043],[@B61-diseases-06-00043]\]
  Timothy syndrome                                           I45.8    *CACNA1C*                                                                                                                                                 601005                                                                                  MO                 \[[@B62-diseases-06-00043]\]
  Diseases of the musculoskeletal system                                                                                                                                                                                                                                                                                                   
  Fibrodysplasia ossificans progressiva (FOP)                M61.1    *ACVR1*                                                                                                                                                   135100                                                                                  mRNA, transgenic   \[[@B63-diseases-06-00043],[@B64-diseases-06-00043],[@B65-diseases-06-00043]\]
  Vasculitis due to ADA2 deficiency                          M30.8    *ADA2*                                                                                                                                                    615688                                                                                  MO                 \[[@B66-diseases-06-00043]\]
  Diseases of the genitourinary system                                                                                                                                                                                                                                                                                                     
  Polycystic kidney disease (PKD)                                     *PKD1*, *PKD2*                                                                                                                                            173900, 613095                                                                          MO, mutant         \[[@B67-diseases-06-00043],[@B68-diseases-06-00043],[@B69-diseases-06-00043]\]
  Congenital malformations                                                                                                                                                                                                                                                                                                                 
  16p11.2 microdeletion/microduplication syndrome                     *KCTD13*                                                                                                                                                  608947                                                                                  MO, mRNA           \[[@B70-diseases-06-00043]\]
  3MC syndrome                                               Q87.8    *COLEC11*, *MASP1*                                                                                                                                        265050, 257920                                                                          MO                 \[[@B71-diseases-06-00043]\]
  Autosomal recessive polycistic kidney disease              Q61.1    *DZIP1L*                                                                                                                                                  617610                                                                                  MO, mutant         \[[@B72-diseases-06-00043]\]
  Axenfeld-Rieger syndrome                                   Q13.8    *PITX2*                                                                                                                                                   180500                                                                                  mutant             \[[@B73-diseases-06-00043]\]
  Bardet-Biedl syndrome (BBS)                                Q87.8    *BBS1*, *BBS2*, *BBS4*, *BBS5*, *BBS6*, *BBS7*, *BBS8*, *BBS10*, *BBS11*, *BBS12*, *CCDC28B*                                                              20991, 600374, 605231, 615981, 615983, 615984, 615985, 615987, 615988, 615989, 610162   MO,                \[[@B74-diseases-06-00043],[@B75-diseases-06-00043],[@B76-diseases-06-00043],[@B77-diseases-06-00043],[@B78-diseases-06-00043],[@B79-diseases-06-00043]\]
  Cardiofaciocutaneous syndrome                              Q87.8    *MEK1*                                                                                                                                                    615279                                                                                  mRNA               \[[@B80-diseases-06-00043]\]
  Coloboma                                                            *GDF6*, *MAB21L2*, *PTCH1*, *YAP1*                                                                                                                        601147, 615877, 601309, 120433                                                          mutant             \[[@B81-diseases-06-00043],[@B82-diseases-06-00043],[@B83-diseases-06-00043],[@B84-diseases-06-00043]\]
  Congenital anomalies of kidney and urinary tract (CAKUT)            *DSTYK*                                                                                                                                                   612666                                                                                  MO                 \[[@B85-diseases-06-00043]\]
  CHARGE syndrome                                            Q87.8    *CHD7*                                                                                                                                                    608892                                                                                  MO, mutant         \[[@B86-diseases-06-00043],[@B87-diseases-06-00043]\]
  COACH syndrome                                             Q04.3    *MKS3*/*TMEM67*                                                                                                                                           216360                                                                                  MO                 \[[@B88-diseases-06-00043],[@B89-diseases-06-00043]\]
  Down syndrome                                              Q90      *21q22.3*                                                                                                                                                 190685                                                                                  mRNA               \[[@B90-diseases-06-00043]\]
  Dyskeratosis congenita                                     Q82.8    *DKC1*, *NOLA3*/*NOP10*                                                                                                                                   305000, 224230                                                                          MO, mutant         \[[@B91-diseases-06-00043],[@B92-diseases-06-00043]\]
  Galloway-Mowat syndrome                                    Q04.3    *OSGEP*, *TPRKB*                                                                                                                                          617729, 617731                                                                          crispant           \[[@B93-diseases-06-00043]\]
  Generalized arterial calcification in infancy (GACI)       Q28.8    *ABCC6*, *ENPP1*                                                                                                                                          614473, 208000                                                                          MO, mutants        \[[@B94-diseases-06-00043],[@B95-diseases-06-00043],[@B96-diseases-06-00043]\]
  Infantile nephronophthisis                                 Q61.5    *ANKS6*                                                                                                                                                   615382                                                                                  MO                 \[[@B97-diseases-06-00043]\]
  Joubert syndrome                                           Q04.3    *JBTS1*/*INPP5E*, *JBTS2*/*TMEM216*, *JBTS3*/*AHI1*, *JBTS5*/*CEP290*, *JBTS7*/*RPGRIP1L*, *JBTS8*/*ARL13B*, *JBTS9*/*CC2D2A*, *JBTS10*/*OFD1*, *ARMC9*   213300, 608091, 608629, 610188, 611560, 610688, 612291, 612285, 300804, 617612          MO, mutant         \[[@B89-diseases-06-00043],[@B98-diseases-06-00043],[@B99-diseases-06-00043],[@B100-diseases-06-00043],[@B101-diseases-06-00043],[@B102-diseases-06-00043],[@B103-diseases-06-00043],[@B104-diseases-06-00043],[@B105-diseases-06-00043]\]
  MARCH syndrome                                                      *CEP55*                                                                                                                                                   610000                                                                                  MO, crispant       \[[@B106-diseases-06-00043]\]
  Pontocerebellar hypoplasia (1B)                            Q04.3    *EXOSC3*                                                                                                                                                  614678                                                                                  MO                 \[[@B107-diseases-06-00043]\]
  Primary ciliary dyskenesia                                 Q34.8    *ARMC4*, *CCDC40*, *ZMYND10*                                                                                                                              615451, 613799, 615444                                                                  MO, mutant         \[[@B108-diseases-06-00043],[@B109-diseases-06-00043],[@B110-diseases-06-00043]\]
  Robinow syndrome (AD)                                      Q87.1    *WNT5A*                                                                                                                                                   180700                                                                                  mRNA               \[[@B111-diseases-06-00043]\]
  Senior-Løken syndrome                                      Q61.5    *SDCCAG8*                                                                                                                                                 613615                                                                                  MO                 \[[@B112-diseases-06-00043]\]
  Spondyloepimetaphyseal dysplasia                           Q77.7    *NANS*                                                                                                                                                    610442                                                                                  MO                 \[[@B113-diseases-06-00043]\]
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###### 

Some examples for the use/test of drugs with human relevance in zebrafish disease models.

  Syndrome                                               Drug/Small Molecule Used         Target/Function                     References
  ------------------------------------------------------ -------------------------------- ----------------------------------- --------------------------------------------------------
  Aortic coarctation                                     GS4012                           VEGF inducer                        \[[@B130-diseases-06-00043]\]
  Blackfan-Diamond anemia                                PF477736                         CHK1 inhibitor                      \[[@B146-diseases-06-00043]\]
  Childhood-onset parkinsonism-dystonia                  Na~2~CaEDTA                      Mn chelator                         \[[@B54-diseases-06-00043]\]
  Dravet syndrome                                        clemizole                        Serotonin modulators                \[[@B55-diseases-06-00043],[@B144-diseases-06-00043]\]
  lorcaserin                                                                                                                  
  Duchenne muscular dystrophy                            Ataluren (PTC124)                Translational readthrough agonist   \[[@B147-diseases-06-00043]\]
  Fibrodysplasia ossificans progressiva (FOP)            Dorsomorphin (and derivatives)   BMP Type 1 Receptor inhibitor       \[[@B142-diseases-06-00043]\]
  Generalized arterial calcification in infancy (GACI)   Etidronate                       PPi analog                          \[[@B95-diseases-06-00043]\]
  Sideroblastic anemia (AR)                              Glycine and folate               supplement                          \[[@B46-diseases-06-00043]\]
  Spondyloepimetaphyseal dysplasia                       Sialic acid                      supplement                          \[[@B113-diseases-06-00043]\]
